Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Inclusion Criteria: * Pathologically confirmed adenocarcinoma of the lung * Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy * At least 1 of the 2 common EGFR mutations known to be associated with EGFR TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations * Treatment-naïve for locally advanced or metastatic NSCLC * WHO performance status score of 0 to 1 with no clinically significant deterioration over the previous 2 weeks before randomization * At least 1 measurable lesion, not previously irradiated and not chosen for biopsy during the study Screening period Exclusion Criteria: * Symptomatic and unstable brain metastases * Leptomeningeal metastases * Symptomatic spinal cord compression * History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD * Any medical conditions requiring chronic continuous oxygen therapy * History of any malignancy other than the disease under study within 3 years before randomization * Any cardiovascular disease as follows: * History of symptomatic chronic heart failure or serious cardiac arrhythmia requiring active treatment * History of myocardial infarction or unstable angina within 24 weeks of randomization